Search results for "Neoplastic"

showing 10 items of 2901 documents

A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in p…

2011

Abstract Purpose: Insulin-like growth factor-1 receptor (IGF-1R) mediates cellular processes in cancer and has been proposed as a therapeutic target. Dalotuzumab (MK-0646) is a humanized IgG1 monoclonal antibody that binds to IGF-1R preventing receptor activation. This study was designed to evaluate the safety and tolerability of dalotuzumab, determine the pharmacokinetic (PK) and pharmacodynamic (PD) profiles, and identify a recommended phase II dose. Experimental Design: Patients with tumors expressing IGF-1R protein were allocated to dose-escalating cohorts of three or more patients each and received intravenous dalotuzumab weekly, every 2 or 3 weeks. Plasma was collected for PK analysis…

AdultMaleCancer ResearchMaximum Tolerated Dosemedicine.medical_treatmentAntineoplastic AgentsPharmacologyAntibodies Monoclonal HumanizedDrug Administration ScheduleReceptor IGF Type 1Insulin-like growth factorPharmacokineticsNeoplasmsmedicineHumansAgedAged 80 and overDose-Response Relationship DrugDalotuzumabbusiness.industryCancerAntibodies MonoclonalMiddle Agedmedicine.diseaseOncologyTolerabilityPharmacodynamicsMonoclonalToxicityFemalebusinessClinical cancer research : an official journal of the American Association for Cancer Research
researchProduct

The use of esmolol in whole-body hyperthermia: Cardiovascular effects

1997

Whole-body hyperthermia (WBH) is a well-described investigational adjunct to systemic chemotherapy for the treatment of advanced malignancies. The hemodynamic consequences of this physiologic state may include tachycardia, which can produce acute myocardial ischemia in patients with coronary artery disease. Ischemic heart disease is currently considered a contraindication to WBH. We chose to investigate the consequences of using a new beta 1-adrenergic antagonist, esmolol, to attempt to control the tachycardia associated with WBH. After institutional approval and patient consent, nine consecutive patients with normal cardiac function presenting for WBH with carboplatin infusion were studied…

AdultMaleCancer ResearchMean arterial pressureCardiac outputHeart diseasePhysiologySinus tachycardiaAdrenergic beta-AntagonistsCardiac indexAntineoplastic AgentsCoronary DiseaseCarboplatinPropanolaminesHeart RateNeoplasmsTachycardiaPhysiology (medical)Heart rateHumansMedicineInfusions Intravenousbusiness.industryContraindicationsHemodynamicsHyperthermia InducedMiddle Agedmedicine.diseaseEsmololCombined Modality TherapyAnesthesiaHeart failureFemaleSafetymedicine.symptombusinessmedicine.drugInternational Journal of Hyperthermia
researchProduct

Ondasetron versus granisetron in the prevention of chemotherapy‐induced nausea and vomiting. Results of a prospective randomized trial

1994

Background. A single‐institution, prospective, randomized open trial was performed to compare ondansetron and granisetron in the prevention of chemotherapyrelated nausea and vomiting. The effect of antemetic drugs was analyzed indipendently for patients treated with highly emetogenic chemotherapy (Study 1), and those treated with moderately emetogenic regimens (Study 2). Methods. In Study 1. 182 patients treated with chemotherapeutic regimens containing high dose cisplatin (more than 70 mg/m2) were randomized to receive 24 mg of ondasentron intravenously (i. v.) or 3 mg of granisetron i. v. for the control of acute emesis. Patients treated with fractionated chemotherapy and those followed‐u…

AdultMaleCancer ResearchNauseaVomitingmedicine.medical_treatmentAntineoplastic AgentsGranisetronchemotherapyDrug Administration Schedulelaw.inventionOndansetronRandomized controlled triallawmedicineHumansgranisetronProspective StudiesProspective cohort studyAgedChemotherapybusiness.industryMiddle AgednauseamovitingOncologyondansetronAnesthesiaAcute DiseaseVomitingFemalemedicine.symptomCisplatinbusinessmedicine.drugChemotherapy-induced nausea and vomiting
researchProduct

Phase I Pharmacokinetic/Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora A Kinase Inhibitor, in Patients with Advanced So…

2012

Abstract Purpose: Aurora A kinase (AAK) is a key regulator of mitosis and a target for anticancer drug development. This phase I study investigated the safety, pharmacokinetics, and pharmacodynamics of MLN8237 (alisertib), an investigational, oral, selective AAK inhibitor, in 59 adults with advanced solid tumors. Experimental Design: Patients received MLN8237 once daily or twice daily for 7, 14, or 21 consecutive days, followed by 14 days recovery, in 21-, 28-, or 35-day cycles. Dose-limiting toxicities (DLT) and the maximum-tolerated dose (MTD) for the 7- and 21-day schedules were determined. Pharmacokinetic parameters were derived from plasma concentration–time profiles. AAK inhibition in…

AdultMaleCancer ResearchNeutropeniaMaximum Tolerated DoseBiopsyAurora A kinaseAntineoplastic AgentsProtein Serine-Threonine KinasesPharmacologyNeutropeniachemistry.chemical_compoundPharmacokineticsAurora KinasesNeoplasmsBiopsyHumansMedicineStomatitisAgedNeoplasm StagingStomatitismedicine.diagnostic_testbusiness.industryCancerAzepinesMiddle Agedmedicine.diseasePyrimidinesOncologychemistryPharmacodynamicsAlisertibFemalebusinessClinical Cancer Research
researchProduct

Demethylation treatment restores hic1 expression and impairs aggressiveness of head and neck squamous cell carcinoma.

2010

Promoter hypermethylation of tumor suppressor genes is a common feature of primary cancer cells. However, at date the somatic epigenetic events that occur in head and neck squamous cell carcinoma (HNSCC) tumorigenesis are not yet been well defined. In the present study we analysed the methylation status of the gene hypermethylated in cancer-1 (hic1), a gene located on chromosome 17p13.3, a region frequently lost in HNSCC. We analysed 22 HNSCC samples and three cell lines using methylation specific PCR (MSP). We found hic1 methylated in 21 out of 22 samples and in all three cell lines. Treatment of the cell lines with the demethylating agent 5-Azacytidin (5-Aza) resulted in the demethylation…

AdultMaleCancer ResearchPathologymedicine.medical_specialtyAntimetabolites AntineoplasticTumor suppressor geneBisulfite sequencingKruppel-Like Transcription FactorsBiologymedicine.disease_causechemistry.chemical_compoundCell Line TumormedicineHumansGenes Tumor SuppressorNeoplasm InvasivenessPromoter Regions GeneticneoplasmsAgedMethylationDNA MethylationMiddle Agedmedicine.diseaseHead and neck squamous-cell carcinomaDemethylating agentGene Expression Regulation Neoplasticstomatognathic diseasesOncologychemistryEpidermoid carcinomaHead and Neck NeoplasmsCancer cellCancer researchAzacitidineCarcinoma Squamous CellFemaleOral SurgeryCarcinogenesisOral oncology
researchProduct

Osteonecrosis of the jaws in patients treated with bisphosphonates - histomorphologic analysis in comparison with infected osteoradionecrosis.

2006

Background:  Patients treated with bisphosphonates because of bone metastases have been shown to develop osteonecrosis of the jaws. In the present study, we examined the histologic findings of these cases. As similarities between this disorder and infected osteoradionecrosis (IORN) are described, both lesions were compared. Methods:  We investigated eight patients with bisphosphonate treatment and osteonecrosis (four female, four male; median age: 65.6 years; cancer: multiple myeloma in five patients, breast cancer in three patients; mandibular involvement in five patients, maxillar involvement in three cases), and 10 patients suffering from IORN (all male; median age: 61.3 years; cancer: s…

AdultMaleCancer ResearchPathologymedicine.medical_specialtyOsteoradionecrosisAdenoid cystic carcinomamedicine.medical_treatmentAntineoplastic AgentsBone NeoplasmsBone resorptionPathology and Forensic MedicineBreast cancermedicineCarcinomaActinomycesHumansMultiple myelomaAgedAged 80 and overBone Density Conservation AgentsDiphosphonatesbusiness.industryOsteonecrosisCancerBisphosphonateMiddle Agedmedicine.diseaseCarcinoma Adenoid CysticOtorhinolaryngologyOsteoradionecrosisCarcinoma Squamous CellPeriodonticsFemaleOral SurgerybusinessJaw DiseasesJournal of oral pathologymedicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology
researchProduct

Prognostic Value of Immunohistochemical Expression of Beta-1 Integrin in Pancreatic Carcinoma

1999

<i>Background: </i>Prognostically relevant factors based on the histological assessment of the resected pancreas are known. However, the knowledge of additional factors associated with the prognosis is helpful in planning the therapy for an individual patient. β<sub>1</sub> Integrin expression is known to have a prognostic influence in some malignant tumors. No data are, however, available on the prognostic value of β<sub>1</sub> integrins in pancreatic carcinoma. <i>Method: </i>We investigated paraffin-embedded specimens of 19 patients undergoing surgical treatment for periampullary carcinoma and of 42 patients for ductal pancreatic carcinoma…

AdultMaleCancer ResearchPathologymedicine.medical_specialtyPancreatic diseaseIntegrinFlow cytometryPredictive Value of TestsBeta 1 integrinHumansMedicineAgedNeoplasm StagingAged 80 and overmedicine.diagnostic_testbiologybusiness.industryCell adhesion moleculeIntegrin beta1CarcinomaGeneral MedicineMiddle AgedPrognosismedicine.diseaseImmunohistochemistryGene Expression Regulation NeoplasticPancreatic Neoplasmsmedicine.anatomical_structureOncologyLymphatic Metastasisbiology.proteinAdenocarcinomaImmunohistochemistryFemalebusinessPancreasOncology
researchProduct

Towards optimal clinical and epidemiological registration of haematological malignancies: Guidelines for recording progressions, transformations and …

2015

AbstractHaematological malignancies (HM) represent over 6% of the total cancer incidence in Europe and affect all ages, ranging between 45% of all cancers in children and 7% in the elderly. Thirty per cent of childhood cancer deaths are due to HM, 8% in the elderly. Their registration presents specific challenges, mainly because HM may transform or progress in the course of the disease into other types of HM. In the context of cancer registration decisions have to be made about classifying subsequent notifications on the same patient as the same tumour (progression), a transformation or a new tumour registration. Allocation of incidence date and method of diagnosis must also be standardised…

AdultMaleCancer ResearchPediatricsmedicine.medical_specialtyTransformationsAdolescentContext (language use)Cancer registrationDiseaseCancer registrationMedical RecordsYoung AdultENCREpidemiologymedicineHumansRegistriesMortalityMedical diagnosisEurocourseChildEarly Detection of CancerAgedAged 80 and overbusiness.industryIncidence (epidemiology)Infant NewbornInfantCancerMiddle Agedmedicine.disease3. Good healthSurgeryCell Transformation NeoplasticOncologyCancer incidenceChild PreschoolHematologic NeoplasmsEpidemiological MonitoringDisease ProgressionFemalebusinessHaematologyEuropean Journal of Cancer
researchProduct

Migration of renal tumor cells depends on dephosphorylation of Shc by PTEN.

2011

The tumor suppressor PTEN is a phosphatase using FAK and Shc as direct substrates, and Akt as a key effector via PIP3. PTEN regulates cell migration and may influence metastases. We quantified PTEN in 135 clear cell renal cell carcinomas (ccRCC) by Western blot analysis and found statistically significant lower PTEN expression in patients who died, usually caused by metastases, within 5 years after surgery, compared to those surviving this time period. In athymic mice, PTEN transfected 786-O cells were injected into the tail vein and metastatic load of the lungs was quantified. We observed a strongly reduced metastatic load after PTEN transfection. For analyses of the PTEN activities, trans…

AdultMaleCancer ResearchSrc Homology 2 Domain-Containing Transforming Protein 1PhosphataseTransplantation HeterologousMice NudeBiologyMiceCell MovementTumor Cells CulturedPTENAnimalsHumansNeoplasm MetastasisPhosphorylationProtein kinase BCarcinoma Renal CellAgedAged 80 and overOncogenePTEN PhosphohydrolaseCell migrationCell cycleMiddle AgedPrognosisSurvival AnalysisKidney NeoplasmsGene Expression Regulation NeoplasticOncologyShc Signaling Adaptor ProteinsLipid phosphatase activityCancer researchbiology.proteinPhosphorylationFemaleInternational journal of oncology
researchProduct

Short telomeres in aggressive non-Hodgkin's lymphoma as a risk factor in lymphomagenesis

2007

Objective Telomeres cap chromosomal ends and help to maintain chromosomal integrity. Telomere shortening may result in chromosomal instability and, ultimately, malignant transformation of cells. It has not been systematically studied whether patients with malignancy have shortened telomeres in their normal, nontransformed cells, which might point to a preexisting disposition for chromosomal instability. Methods We designed an (age-) matched pair analysis that compared telomere length in nonmalignant peripheral leukocytes from previously untreated patients who recently developed an aggressive non-Hodgkin's lymphoma, with leukocytes from healthy individuals. Results Telomere lengths in B and …

AdultMaleCancer ResearchTelomeraseT-LymphocytesBiologyMalignancyMalignant transformationRisk FactorsChromosome instabilityGeneticsmedicineChromosomes HumanHumansRisk factorMolecular BiologyB-LymphocytesLymphoma Non-HodgkinCell BiologyHematologyTelomeremedicine.diseaseLymphomaNon-Hodgkin's lymphomaTelomereOxidative StressCell Transformation NeoplasticImmunologyFemaleGranulocytesExperimental Hematology
researchProduct